Receptor News and Research

RSS

Study aims to identify markers that predict how COVID-19 affects patients

COVID-19 is the UK's largest public health crisis since World War II. There is an urgent need to identify why some patients with the virus do very well whereas others need to be admitted to intensive care and may die from the disease.

18 May 2020

Avacta's SARS-COV-2 neutralizing Affimer reagents show therapeutic potential for COVID-19

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway.

From Avacta Life Sciences Ltd. 18 May 2020

Research explores how human enzymes could be used to exacerbate COVID-19

Centenary Institute researchers have examined the critical role of human enzymes and the coronavirus in a newly published scientific review article that explores potential strategies for COVID-19 disease treatment and management.

18 May 2020

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Takeda Pharmaceutical Company Limited today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two upcoming virtual scientific congresses: the 56th Annual Meeting of the American Society of Clinical Oncology, May 29-31 and the 25th Virtual Congress of the European Hematology Association, June 11-14.

18 May 2020

Host-virus interaction drives adaptive mutation in bat CoV related to SARS-CoVs

Virus and receptor diversity is shaped by the need to evolve advanced weaponry to facilitate virus entry and infection, on the one hand, and host resistance, on the other. A new paper published on the preprint server bioRxiv* shows how this mechanism operates in a bat coronavirus, which is related to the earlier SARS coronavirus.

17 May 2020

New and unexplored angle in the binding of SARS-CoV-2 to host cells

Researchers in the Netherlands, Cuba, and Italy have made important discoveries about the carbohydrate-mediated binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to host cell lectin receptors and host lung microbiota.

17 May 2020

Well-known cancer drugs may prevent SARS-CoV-2 viral replication say researchers

Researchers in Frankfurt, Germany, have described cell signaling events that occur when severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells and have identified pathways that are essential for the virus to replicate.

17 May 2020

Study shows human monoclonal antibodies can effectively neutralize SARS-CoV-2

US researchers have published a proof of concept on the efficacy of human monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in laboratory conditions, as well as their pioneering use in a mouse model. The study is available on the preprint server bioRxiv*.

17 May 2020

UCLA-led clinical trial to assess if hormone suppresser will reduce COVID-19 severity in men

UCLA researchers have launched a new clinical trial that uses a hormone suppresser commonly used to treat men with prostate cancer to help improve clinical outcomes for men infected with COVID-19.

15 May 2020

Researchers investigate the troubling trend of heart injury in COVID-19 patients

Researchers are finding about half of all patients with COVID-19 admitted to an intensive care unit have heart damage.

15 May 2020

Text reminders are not a silver bullet to improve breast cancer hormone therapy adherence

Text message reminders are not a silver bullet when it comes to overcoming the long-standing challenge of ensuring that breast cancer patients continue to take aromatase inhibitors, pills to treat hormone-sensitive cancers that are prescribed for as long as five years.

14 May 2020

More cancer patients could benefit from CAR T-cell therapy, Moffitt study suggests

Chimeric antigen receptor T-cell therapy, or CAR T, has become a game changer for lymphoma and leukemia patients who have relapsed or become resistant to previous treatments.

14 May 2020

11 healthcare centers participate in clinical trial of Russian drug against novel coronavirus

Initially, the drug was developed to treat rheumatoid arthritis. BIOCAD developers receive regulatory authorization as part of the procedure approved by Decree No. 441 of the Government of the Russian Federation of April 4, 2020 since the mechanism of action of the active substance is associated with the cytokine storm, a life-threatening immune system response in patients with COVID-19.

14 May 2020

A promising treatment for chronic inflammatory liver disease

Primary sclerosing cholangitis (PSC) is a rare, chronic, inflammatory disease of the bile ducts and is difficult to treat.

14 May 2020

Study: Neurons expressing dopamine D2 receptors have different molecular features, functions

An international collaboration, which included the involvement of the research team from the Institut de Neurociències of the UAB (INC-UAB), has shown that neurons expressing dopamine D2 receptors have different molecular features and functions, depending on their anatomical localization within the striatum.

14 May 2020

Does HIV infection increase the severity of COVID-19?

A new study by researchers at the New York University Grossman School of Medicine and published on the preprint server medRxiv* in May 2020 reports that being infected with HIV at the time of acquiring COVID-19 does not significantly increase the severity of illness or the risk of complications.

13 May 2020

U of A researchers and Tonix Pharmaceuticals join forces to develop, test COVID-19 vaccine

University of Alberta researchers launched a joint effort with U.S.-based Tonix Pharmaceuticals to develop and test a vaccine against COVID-19.

13 May 2020

Vaccine design can face specific challenges, say researchers

The goal of a vaccine is to trigger a response that safely protects against an infection and/or the burden of disease.

13 May 2020

Processes underlying the damaging effects of brain injury can preserve memory function

A study examining the effect of the immune receptor known as Toll-like Receptor 4, or TLR4, on how memory functions in both the normal and injured brain has found vastly different cellular pathways contribute to the receptor's effects on excitability in the uninjured and injured brain.

13 May 2020

Analysis of single-cell data indicates that SARS-Cov-2 targets many cell types

Before it can sicken people, the new coronavirus must first sneak into their cells. But not any cell will do. The virus can enter only those with a certain combination of molecules on their surfaces.

13 May 2020

Receptor News and Research

Study aims to identify markers that predict how COVID-19 affects patients

Avacta's SARS-COV-2 neutralizing Affimer reagents show therapeutic potential for COVID-19

Research explores how human enzymes could be used to exacerbate COVID-19

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Host-virus interaction drives adaptive mutation in bat CoV related to SARS-CoVs

New and unexplored angle in the binding of SARS-CoV-2 to host cells

Well-known cancer drugs may prevent SARS-CoV-2 viral replication say researchers

Study shows human monoclonal antibodies can effectively neutralize SARS-CoV-2

UCLA-led clinical trial to assess if hormone suppresser will reduce COVID-19 severity in men

Researchers investigate the troubling trend of heart injury in COVID-19 patients

Text reminders are not a silver bullet to improve breast cancer hormone therapy adherence

More cancer patients could benefit from CAR T-cell therapy, Moffitt study suggests

11 healthcare centers participate in clinical trial of Russian drug against novel coronavirus

A promising treatment for chronic inflammatory liver disease

Study: Neurons expressing dopamine D2 receptors have different molecular features, functions

Does HIV infection increase the severity of COVID-19?

U of A researchers and Tonix Pharmaceuticals join forces to develop, test COVID-19 vaccine

Vaccine design can face specific challenges, say researchers

Processes underlying the damaging effects of brain injury can preserve memory function

Analysis of single-cell data indicates that SARS-Cov-2 targets many cell types

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News